The objectives of this study are: (1) to evaluate the response rate, (2) to evaluate the qualitative and quantitative toxicities, and (3) to evaluate time to treatment failure of carboplatin and thymidine in patients with recurring malignant glioma.
Showing the most recent 10 out of 459 publications